A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).

Authors

Sven De Vos

University of California, Los Angeles Medical Center, Los Angeles, CA

Sven De Vos , Laurie Helen Sehn , Stephen P. Mulligan , Martin H. Dreyling , Mathias J. Rummel , Pier Luigi Zinzani , David Michael Johnson , Shelley Evans , Roger D. Dansey , Wayne R. Godfrey , Myron Stefan Czuczman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).

First Author: Herbert Aaron Eradat

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.

First Author: Gilles A. Salles

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).

First Author: John Leonard

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).

First Author: Herbert Aaron Eradat